Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYLYNK-001: Pembrolizumab and Olaparib in First-Line Treatment of Advanced Epithelial Ovarian Cancer
NCT03740165Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2018
- Primary completion
- Aug 2024
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab and olaparib in ovarian cancer, fallopian tube cancer (PFTC) and peritoneal neoplasm (3 arms), sponsored by Merck & Co. Primary endpoints: Progression-Free Survival Per RECIST 1.1 in Participants With PD-L1 Positive Tumors (CPS>=10) at 67 months and Progression-Free Survival Per RECIST 1.1 in All Participants at 67 months. Started Dec 2018; status: completed.
02
Drugs
pembrolizumabolaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)peritoneal neoplasm
Beyond the preview
Go deeper on NCT03740165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03740165.